Epidemiology and risk factors of stroke in the Americas: a comprehensive narrative literature review Authors: Gisele Sampaio Silva, Jose Danilo Diestro, Christopher Tarzi, Teruko Kishibe, Antonio Bernabé-Ortiz, Rodrigo M Carrillo-Larco, Bruce Ovbiagele, Gustavo Saposnik, Carlos Abanto, Matias Alet, Bassel Almarie, Tony Fabián Alvarez, Pablo Amaya, Sebastian Ameriso, Antonio Arauz, Miguel A Barboza, Hernán Bayona, Juan Calleja, Vanessa Cano-Nigenda, Leonardo Augusto Carbonera, Angel Corredor, Ana Cláudia de Souza, Felipe Fregni, Rodrigo Guerrero, Claudio Jimenez, Fernando Lanas, Ramón Martinez, Sheila Martins, Paula Muñoz-Venturelli, Victor Navia, Nelson Novarro-Escudero, Verónica V Olavarría, Octavio Pontes-Neto, Pedro Ordunez, Virginia Pujol, Alejandro A Rabinstein, Julieta Rosales, Andres Rosende, Souvik Sen, Luciano Sposato Published: 2026 ABSTRACT SummaryStroke remains a leading cause of death and disability across the Americas, disproportionately affecting low- and middle-income countries. According to the 2023 Global Burden of Disease (GBD) Study, the Americas recorded approximately 1.2 million incident strokes and 15.7 million prevalent cases. This narrative review synthesizes epidemiological evidence on stroke trends in the Americas, with emphasis on disparities in healthcare access. We integrated estimates from the GBD, peer-reviewed studies and national surveillance systems. Although age-standardized stroke rates declined after 1990, recent analyses demonstrate a concerning resurgence, particularly among younger adults. Stroke incidence, prevalence, and disability burden vary widely across countries. Latin America and the Caribbean show higher incidence but lower prevalence than high-income settings, reflecting limited access to acute care and higher case fatality. Socioeconomic and racial inequities drive delayed treatment and poorer functional outcomes. Over 75% of stroke burden is attributable to modifiable risk factors. Urgent system-level action is needed.Keywords: Stroke, Burden, Risk factors, Americas, Sex, Race, Ethnicity, Disparities Introduction With accelerating global socioeconomic development, the prevalence of communicable diseases in low- and middle-income countries (LMICs) has declined, while the burden of cardiovascular and cerebrovascular diseases, once predominantly affecting high-income countries, has increasingly shifted to LMICs. In 2021, stroke, comprising ischemic and haemorrhagic stroke, including intracerebral hemorrhage and subarachnoid hemorrhage, was the third leading cause of death and the fourth leading cause of disability-adjusted life years (DALYs) globally.1 Notably, stroke remains the foremost contributor to years lived with disability (YLDs), reflecting its significant long-term impact on functional independence.2 Recent estimates report 93.8 million individuals living with stroke worldwide and 11.9 million incident cases in 2021.1 Projections warn that, if current trends in risk factors continue, global stroke incidence could rise 81% by 2050.3 Regionwide, stroke accounted for 0.5 million deaths and 11.4 million stroke-related DALYs in 2021.4 In Latin America and the Caribbean (LAC) alone, over 90% of stroke-attributable DALYs could potentially be prevented by achieving guideline-recommended targets for modifiable risk factors, specifically systolic blood pressure and body mass index (BMI), responsible for 53% and 37% of DALYs, respectively.5 Addressing social determinants remains critical, as racial inequities persist, with African Americans experiencing delayed stroke care and lower access to reperfusion therapies.6 In this context, there is a need to examine comprehensively the current epidemiology of stroke and its predominant risk factors within the region. This review provides a comprehensive overview of the epidemiology and risk factors of stroke across the Americas, drawing on data from six subregions as defined by the Global Burden of Disease (GBD) Study (Supplementary Table S1). We examine metabolic, behavioral, environmental, and occupational risk factors, including region-specific contributors such as Chagas disease, to understand their impact on stroke incidence, care, and outcomes, highlighting opportunities for targeted, regionally tailored public health strategies across the Americas. Search strategy and article selection A specialist conducted a targeted review of stroke epidemiology and risk factors across the Americas, emphasizing disparities, restricting searches to studies published from 2015 onward. To examine prominent risk factors for stroke burden, we drew data from the GBD Study 2021 estimates based on the comparative risk assessment framework, as described elsewhere.1 Additionally, we conducted a search in OVID Medline and LILACS (Latin American and Caribbean Literature on Health Sciences) without language restriction for articles published from January 2015 to February 2025, using search terms related to conditions (e.g., stroke, cerebrovascular disease, ischemic stroke, hemorrhagic stroke, intracerebral hemorrhage, subarachnoid hemorrhage), geography (e.g., Americas, LAC, North America, United States, Canada, Mexico, Argentina, Chile, Colombia), risk factors (e.g., sex, race, high fasting blood glucose, dietary patterns, environmental exposures, Chagas disease, sleep apnea, oral hygiene), and stroke outcome measures (e.g., prevalence, incidence, deaths, DALYs). The full search strategy is available in the Supplementary Materials (see Supplementary Methods for the full strings and counts). All identified articles were imported into the Covidence platform, where three authors (CT, JBD, GS) independently screened titles and abstracts for relevance based on predefined inclusion criteria: series or reviews done after 2015 in any of the aforementioned regions (Southern Latin America, High-income North America, and LAC).7 We included original research (population-based cohort, cross-sectional, and case-registry studies), national surveillance and administrative reports, and systematic reviews/meta-analyses published from 2015 onwards that reported stroke epidemiology, risk-factor attribution, or health-system outcomes for populations in the target regions. Single-country studies were eligible if they provided any of the prespecified outcomes (incidence, prevalence, mortality, DALYs, risk-factor contribution, or measures of access to acute stroke care and rehabilitation). In addition to the database search, key landmark studies identified by the authors were included to ensure comprehensive coverage. Therefore, our synthesis draws on the GBD (2021 and 2023 when available) results and peer-reviewed primary studies. This manuscript presents an integrative review of existing data rather than new primary epidemiological findings. Epidemiological overview of stroke in the Americas Prevalence and incidence of stroke According to the 2023 GBD Study, the Americas recorded approximately 1.2 million incident strokes and 15.7 million prevalent cases.8 While absolute stroke numbers increased over time, age-standardized incidence and prevalence generally declined across the region between 1990 and 2021, mirroring global trends. For example, the age-standardized incidence of stroke in the Region of the Americas decreased from 143.23 per 100,000 in 1990 to 93.37 per 100,000 in 2021 and 91.58 per 100,000 in 2023.8 Although long-term declines in stroke rates were observed across many age groups, this trend appears to have flattened or reversed in recent years (Fig. 1).4 From 2015 to 2021, the incidence increased overall, among younger adults (<50 years).4 This pattern may reflect changing epidemiological dynamics rather than the sudden emergence of new causes: widely recognized drivers (increasing prevalence of obesity, diabetes, and metabolic syndrome, greater sedentary behavior, and worsening ambient air pollution in some settings) have intensified or shifted toward younger cohorts in recent decades and therefore plausibly contribute to the observed recent uptick in incidence.9 A comparative analysis of stroke incidence and prevalence between the Americas and other global regions. Source: The Global Burden of Disease Study 2023 (GBD). Institute for Health Metrics and Evaluation. Global Burden of Disease Results Tool (GBD 2023). 2024; published online Jan. https://vizhub.healthdata.org/gbd-results/ (accessed Feb 9, 2026). Notes: Shaded band areas around the solid lines indicate the 95% uncertainty interval of the estimates. Regionally, LAC now represent the fourth highest global burden of stroke in absolute terms, following East Asia, South Asia, and Southeast Asia.5 A prior systematic review of studies conducted between 1997 and 2002 estimated the crude annual incidence of first-ever stroke in LAC at 119 per 100,000 people.10 According to updated GBD 2023 data, the age-standardized incidence in the LAC region was 96.57 per 100,000, with a prevalence of 993.65 per 100,000, incidence notably higher and prevalence substantially lower than in high-income North America, where the incidence was 86.65 per 100,000 and prevalence 1438.44 per 100,000.8 The higher incidence in LAC may reflect weaker stroke prevention strategies, including limited control of risk factors. The lower prevalence, despite a higher incidence, suggests a higher case fatality rate in LAC, maybe driven by disparities in access to acute stroke care. Although incidence continues to decline across the Americas, the pace of improvement is increasingly outstripped by that seen in regions such as Europe and Central Asia, particularly after 2010, as demonstrated by the steeper downward slopes in Fig. 1. High-income North America, long viewed as a benchmark for stroke prevention and acute care, now shows slower improvement and is increasingly surpassed by Southern Latin America, which demonstrates lower age-standardized incidence and prevalence. These trends likely reflect stronger population-level risk-factor control. Similar convergence is observed across North Africa, Middle East, Latin America and the Caribbean, driving reductions in stroke. Stratifying countries by Sociodemographic Index (SDI) further highlights these inequalities. Fig. 2 shows scatterplots of country-level SDI versus age-standardized stroke incidence (panel A) and versus age-standardized stroke prevalence (panel B) for 2021. Countries with lower SDI cluster toward higher incidence but lower prevalence, consistent with the interpretation that lower-SDI settings experience both greater stroke occurrence and worse post-stroke survival. For example, Haiti (SDI 0.448) has a substantially higher incidence than the LAC average while showing only a modestly increased prevalence, whereas Canada (SDI 0.873) and the United States (SDI 0.862) lie at the high-SDI, lower-incidence/higher-prevalence end of the distribution. These scatterplots summarize the relationship between sociodemographic development and both components of stroke burden and reinforce that disparities reflect inequities in primary prevention and in survival after stroke (Country SDI values are listed in Supplementary Table S2). Regional stroke burden differences reflect demographic structure, risk-factor prevalence and control, health-system capacity, and social determinants, with some variation influenced by surveillance, coding, and case-ascertainment differences. Age-standardized rates per 100,000 population in incidence and prevalence from stroke against the socio demographic index by countries of the Americas, 2021. Source: The Global Burden of Disease Study 2021. Each circle represents a country, which is identified by the three alphabetical letter ISO 3166-1 code. Countries are color-coded by the SDI quintile and the circle size is proportional to the population size of the country in 2021. SDI, Socio Demographic Index. Stroke subtypes: Ischemic versus Haemorrhagic In 2021, ischemic stroke accounted for approximately 70% of all new stroke cases in the Americas, while intracerebral hemorrhage and subarachnoid hemorrhage comprised the remaining 30%.4 Although the overall incidence and mortality from stroke have declined in the region, this aggregate trend conceals important age-specific disparities. Between 1990 and 2021, stroke incidence among individuals under 50 years showed a more pronounced upward trend, measured by average annual percent change, for both ischemic and haemorrhagic stroke subtypes4 These trends point to a worrying rise in early-onset stroke, potentially reflecting increases in obesity, infective endocarditis (particularly related to intravenous drug use), stimulant drug use, sedentary lifestyle and smoking.9 Within LAC, ischemic stroke is the most frequent subtype, yet intracerebral hemorrhage drives the greatest burden by age-standardized DALYs, accounting for 42% of regional stroke DALYs.5 Ischemic stroke contributes to long-term disability, reflected in higher YLDs. Southern Latin America and LAC show higher intracerebral hemorrhage proportions than High-Income North America. This disproportionate burden of intracerebral hemorrhage in LMIC regions may reflect a confluence of factors that result in suboptimal primary stroke prevention (Fig. 3). Age-standardized incidence rates due to Stroke Subtypes by sex across regions of the Americas, globally and GBD super-regions in 2023. Source: The Global Burden of Disease Study 2023 (GBD). Institute for Health Metrics and Evaluation. Global Burden of Disease Results Tool (GBD 2023). 2024; published online Jan. https://vizhub.healthdata.org/gbd-results/ (accessed Feb 9, 2026). Women bear a disproportionate burden of subarachnoid hemorrhage across all metrics—including DALYs, YLDs, years of life lost, and mortality. This pattern may relate to sex differences in aneurysm formation and rupture risk, as well as potential disparities in recognition and treatment. Mortality from stroke In 2021, stroke accounted for approximately 500,000 deaths in the Americas, with ischemic stroke responsible for 55% of these fatalities, and 45% attributable to intracerebral hemorrhage and subarachnoid hemorrhage4 Stroke has consistently ranked as the second leading cause of death in the region, surpassed only by ischemic heart disease, except during the peak of the COVID-19 pandemic, when COVID-19 temporarily became the leading cause of mortality.4 Despite the high absolute burden, the age-standardized incidence and mortality of stroke have declined over recent decades (Figs. 1 and 4). Declines in stroke incidence and mortality reflect advances in primary prevention, including wider use of antihypertensives, antithrombotics, statins, and tobacco control. Brazil and Chile achieved improvements in hypertension treatment and control, as shown in global analyses.11 Advances in acute in-hospital stroke care have improved regional outcomes. In Brazil, a landmark national study demonstrated that endovascular thrombectomy for large vessel occlusion is feasible and effective in middle-income, resource-constrained settings.12 This underscores the central role of political commitment and targeted health-system investment in expanding access to high-impact stroke therapies. Age-standardized stroke mortality and disability-adjusted life years (DALYs) comparing the Americas with the rest of the world. Source: The Global Burden of Disease Study 2023 (GBD). Institute for Health Metrics and Evaluation. Global Burden of Disease Results Tool (GBD 2023). 2024; published online Jan. https://vizhub.healthdata.org/gbd-results/ (accessed Feb 9, 2026). Shaded band areas around the solid lines indicate the 95% uncertainty interval of the estimates. Population growth and aging are expected to drive a 67% rise in stroke deaths and a 41% rise in DALYs in the region between 2021 and 2050.3 Although the Americas’ age-standardized DALY rate for stroke (869.15/100,000) is below the global average (1886.20/100,000), absolute DALY totals are concentrated in large countries (Brazil, then Mexico), while age-standardized rates, which adjust for population age structure, are highest in Haiti (4041.65/100,000), highlighting important differences between per-person risk and total population burden. In fact, Haiti consistently bears the highest burden across all three stroke subtypes. While countries with higher sociodemographic development (SDI quintiles 4–5) generally exhibit stable or increasing stroke incidence, these trends are not paralleled by increases in mortality or DALYs, likely reflecting greater access to acute care, secondary prevention, and rehabilitation services. In contrast, many countries with lower SDI levels continue to experience substantial and rising mortality and disability burden, highlighting ongoing health system gaps. As shown in Fig. 5, countries such as the USA, Puerto Rico, and Bermuda demonstrate increasing incidence but stable or declining mortality.4 Conversely, countries like Jamaica and Saint Lucia, in lower SDI quintiles, exhibit concurrent increases in incidence and mortality. Notably, Venezuela, a country in the lowest SDI quintile, demonstrates rising mortality despite decreasing incidence, suggesting worsening outcomes among those affected. Association between sociodemographic development and trends in stroke burden across countries in the Americas, 2015–2021. Panels show (A) stroke incidence, and (B) stroke deaths, expressed as age-standardized rates per 100,000 population in 2021, plotted against the average annual percent change (AAPC) between 2015 and 2021. Each bubble represents one country; bubble size corresponds to total population size. Countries are color-coded by Sociodemographic Index (SDI) quintile, with lower SDI quintiles indicating lower levels of socioeconomic development. The dashed horizontal line indicates the 75th percentile for each outcome; the vertical dashed line represents an AAPC of 0 (no change over time). Each country is labeled with the ISO 3166 three-letter (alpha-3) country code. (Figure adapted from Martinez et al: https://doi.org/10.1016/j.lana.2025.101017). Disparities in stroke burden Sex and age disparities in stroke In LAC, despite a steady decline in age-standardized stroke incidence since 1990, recent trends show a reversal among younger populations (<55 years), particularly in women. This increase is nearly twice as pronounced in women compared to men and is even more evident among those under 45 years of age.13 Among young adults aged 20–49 years, GBD trends reveal reversal after prolonged declines. Between 2015 and 2021, overall and ischemic stroke incidence increased across most age strata, more prominently in female patients. Mortality and DALY rates also rose, with average annual percent changes exceeding 1.4%.4 People >70 years of age remain the most affected by stroke in terms of prevalence, mortality, DALYs, with global projections indicating a sharp rise in stroke burden among those over 85 years by 2050. This trend is expected to be most dramatic in upper-middle and lower-middle-income countries.3 Stroke outcomes in women vary, with generally better short-term survival but increased risk of lasting disability and poorer quality of life compared to men In 2019, LAC data showed that men contributed a slightly larger share of years of life lost and DALYs while women had higher YLDs and stroke-related mortality.5 This pattern is compatible with two non-mutually exclusive explanations: men may experience strokes at younger ages (yielding more years of life lost per event), while women may have strokes at older ages and/or experience higher case-fatality. Sex-based differences in stroke outcomes have also been observed in response to acute interventions. For instance, women have been shown to have worse outcomes following endovascular thrombectomy compared to men, though the underlying biological mechanisms remain unclear.14 The loss of estrogen after menopause is one potential factor, given its established cardioprotective properties.15,16 These findings support the notion that the delayed but prolonged stroke burden in women may be biologically mediated. Together, these findings highlight sex-based differences in stroke-related DALYs across the Americas. Higher DALYs in men reflect premature stroke and mortality, whereas women experience stroke later, with disability predominating. Evidence indicates disparities in acute care, including lower thrombolysis rates and longer treatment delays among women.17 Global/region-level analyses indicate lower direct oral anticoagulants prescribing despite elevated stroke risk in some female patient subgroups18 Beyond clinical management, social and psychological determinants, such as lower educational attainment, being unmarried, and pre-stroke depression, have been associated with poorer post-stroke survival in women in the USA.19 Physician bias may also play a role: in a Canadian multicenter study, women were more likely than men to be misdiagnosed with stroke mimics following transient or minor neurological symptoms.20 Diagnostic delays may further exacerbate sex disparities in acute stroke care. Also in Canada, women with stroke received 3% less healthcare spending on average compared to men.21 These multifactorial, and often underrecognized, disparities warrant urgent attention to ensure equitable stroke care across sexes in the Americas.22,23 Risk-factor trends show sex-specific patterns: reductions in alcohol use and improved glucose control drove better outcomes in men, while women benefited more from lower sodium intake, reduced smoking, and decreased BMI.13,23 Behavioral risk factors, particularly smoking, unhealthy diet and physical inactivity, remain more prevalent among younger men, whereas metabolic risk factors, including hypertension, raised BMI and dyslipidaemia, predominate in older adults and increase markedly among post-menopausal women.5 Finally, the interplay between age of onset and national income level reveals stark inequalities. Globally, in LMICs, stroke occurs on average 5.5 years earlier than in high-income countries.6 This premature burden among working-age adults further entrenches cycles of poverty, as younger stroke survivors are less able to contribute economically, exacerbating health and development disparities.13 Socioeconomic disparities within countries and among countries As communicable disease burdens have declined, LMICs have seen a shift toward non-communicable diseases. In fact, the crude incidence of stroke in LMICs surpassed that in high-income countries (HICs) in 2010.6 Higher stroke prevalence in high-income North America, despite similar incidence to LMIC regions, likely reflects improved survival with long-term disability rather than increased acute stroke mortality. Several factors may underlie these disparities, one of them being unequal access to EVT, a transformative treatment for large vessel occlusion ischemic stroke introduced in the past decade. Findings from the Mission Thrombectomy 2020+ (MT2020+) study revealed that in most countries across LAC, fewer than 10% of eligible large vessel occlusion stroke patients received endovascular thrombectomy. In contrast, utilization rates were significantly higher in the United States and Canada, reaching 41–47% and 31–40%, respectively. A key determinant of endovascular thrombectomy availability and access was a country's gross national income per capita, underscoring the intersection of economic capacity and healthcare infrastructure in determining stroke outcomes.24,25 These global observations are supported by national data; for instance, surveys conducted in Mexico identified the absence of public funding for endovascular thrombectomy and the high cost of medical devices as major barriers to implementation and equitable access.26 In Latin America, the cost of endovascular thrombectomy is estimated to be approximately 3.1 times higher than that of standard medical therapy, necessitating substantial reallocation of limited healthcare resources to support broader implementation.27 Despite advances in cardiovascular and stroke care, access remains unequal. PURE Study data from South America showed only 4.1% of individuals with cardiovascular disease in LMICs received all guideline-recommended secondary prevention medications.28 Even within the same countries, socioeconomic disparities still exist. A case study from Brazil illustrates the structural determinants of stroke outcomes: income inequality was independently associated with stroke mortality at the federal district level, even after adjusting for gross domestic product (GDP) per capita, urbanization, and healthcare spending. These findings highlight how inequitable income distribution translates into excess mortality, making a compelling case for addressing social determinants of health in the region.29 Even in Canada's universal healthcare system, access disparities persist: population-based studies show materially deprived groups are significantly less likely to receive intravenous thrombolysis or mechanical thrombectomy than least deprived groups.30,31 Similarly, in the United States, counties characterized by low insurance coverage, high social deprivation indices, and a population with >10% Black residents were associated with increased stroke mortality.32 These inequities are further exacerbated by structural deficiencies. Hospitals in these underserved areas were found to be 20–42% less likely to attain stroke center certification, limiting access to guideline-based stroke care where it is most urgently needed.33 Greater health expenditure does not necessarily yield better stroke outcomes. Despite higher GDP per capita in the United States than in Canada in 2021, stroke mortality and DALYs have been consistently lower in Canada since 2000 (Fig. 6). Similarly, within Latin America, Argentina, whose GDP per capita and SDI are higher than that of Brazil (US$10,738 versus US$7972), nevertheless shares a similar incidence and higher prevalence of stroke compared to Brazil.4 (Fig. 2). Age-standardized death and disability adjusted life years rates per 100,000 population from stroke in the United States of America and Canada from 1980 to 2021. Source: The Global Burden of Disease Study 2021(GBD). Shaded band areas around the solid lines indicate the 95% uncertainty interval of the estimates. Racial and ethnic disparities Across the Americas, the burden of stroke continues to reflect deep-rooted racial and ethnic disparities, shaped by systemic inequities in access to care, socioeconomic conditions, and structural racism. In the United States, the incidence of first ischemic stroke is more than twice as high among Black individuals compared to white individuals (1.91 versus 0.88 per 1000), with strokes occurring at younger ages and associated with greater mortality and disability.6,34 Asian and Pacific Islander individuals have higher intracerebral hemorrhage mortality, while Mexican Americans face increased recurrent stroke risk and mortality compared with non-Hispanic White populations.35 Hispanic and Native American communities also carry a disproportionate burden, with higher hospitalization rates for stroke and lower access to acute interventions like thrombolysis and thrombectomy.6 Indigenous populations in Latin America, particularly those in rural and underserved regions, face similar barriers, with high incidence and case fatality largely attributable to delayed access to neuroimaging and specialized care. The Strong Heart Study reported an age- and sex-adjusted first-stroke incidence of 679 per 100,000 person-years among American Indian participants.36 Notably, a systematic review of stroke incidence in Latin America revealed a range from 73.6 to 180.4 per 100,000.10 Worse health outcomes among Indigenous and Afro-descendant populations have been consistently reported worldwide when compared to the Caucasian population.6,37 These disparities are exacerbated by limited access to rehabilitation. In the United States, Black and Hispanic patients receive less inpatient rehabilitation, present later, receive fewer preventive therapies, and experience poorer functional outcomes.38 In Latin America, systemic underfunding of rehabilitation infrastructure has led to particularly poor access in Indigenous and rural communities. The shortage of trained multidisciplinary teams and follow-up services exacerbates disability, reinforcing cycles of poverty and limited social mobility.39,40 Reducing disparities requires structural reforms and culturally tailored community programs addressing hypertension and diabetes in marginalized populations.41 In particular, the successful reduction of end-stage renal disease disparities among Native Americans in the U.S. through targeted interventions serves as a potential model for stroke equity initiatives.42 Moreover, results from the GBD Study emphasize that without disaggregated data and granular surveillance, disparities in stroke incidence, mortality, and disability will remain poorly addressed across the Americas.1 Prioritizing marginalized populations in research, registries, and equitable policies is essential to reduce stroke disparities across the continent.41 Major risk factors for stroke in the Americas GBD 2021 estimates indicate that stroke is largely preventable: in 2021, 77% of the stroke burden in the Americas was attributable to 20 modifiable risk factors, including hypertension, elevated LDL cholesterol, smoking, hyperglycaemia, air pollution, obesity, unhealthy diet, kidney disease, excess sodium and alcohol intake, and physical inactivity. Updated GBD 2023 data show similar findings, with non-optimal temperature newly emerging among the 10 leading stroke risk factor (Fig. 7).1 Age-standardized disability-adjusted life years lost due to stroke attributable to the top ten risk factors in the Region of the Americas, High-income North America, Latin America and Caribbean, and Southern Latin America in 2023. Source: The Global Burden of Disease Study 2023 (GBD). Institute for Health Metrics and Evaluation. Global Burden of Disease Results Tool (GBD 2023). 2024; published online Jan. https://vizhub.healthdata.org/gbd-results/ (accessed Feb 9, 2026). Data are shown as a percentage of the population attributable fraction of stroke disability-adjusted life years attributable to risk factors. Black lines represent the 95% uncertainty interval of the estimates. Metabolic risk factors Metabolic risk factors accounted for the largest proportion of the stroke burden both globally and in LAC, contributing to 70.97% and 70.14% of DALYs, respectively in 2021, with similar proportions in 2023. High systolic blood pressure and elevated BMI were consistently identified as the leading modifiable risk factors. In LAC, high systolic blood pressure alone accounted for more than 50% the stroke-related DALYs (52% in 2021 and 56.9% in 2023), while high BMI was responsible for 9.3% in 2021 and 8.3% in 2023.1 This pattern is consistent across all age groups and sexes and is especially pronounced in intracerebral hemorrhage and subarachnoid hemorrhage.5 If effectively addressed, these two factors alone could reduce the regional stroke burden more than 70%, underscoring the potential impact of scalable interventions targeting hypertension and obesity.5,43 The prevalence of key metabolic conditions in the LAC region continues to climb and fuels the growing stroke burden. Age-standardized hypertension prevalence declined in Canada, reaching among the lowest globally by 2019 (≈24% of men, 20% of women). In the United States, prevalence remained largely unchanged at approximately 34% in men and 29% in women. In contrast, most Latin America and Caribbean countries showed increases or minimal change since 1990, with highly heterogeneous 2019 prevalence ranging from about 18% to 62%. Obesity has become a major public health challenge, particularly in upper-middle-income countries in LAC, while diabetes and elevated fasting glucose levels are among the top-ranked stroke risk factors in the region.5,44 Between 1990 and 2019, diabetes prevalence increased worldwide, rising from 4.1% to 6.3% in men and from 3.7% to 5.3% in women. In North America and LAC, prevalence increased above averages. As of 2019, North America had age-standardized prevalence rates of 9.2% in men and 7.1% in women, while in LAC the rates were 7.4% and 6.6%, respectively.44 These conditions not only increase stroke incidence but also contribute significantly to YLDs, straining healthcare systems and impairing long-term quality of life for survivors.4,5 Notably, despite progress in reducing stroke mortality in countries like Brazil and Argentina, the persistent high prevalence of metabolic risks indicates a pressing need for targeted primary and secondary prevention strategies.4,43 Socioeconomic disparities exacerbate the impact of metabolic risk factors on stroke outcomes in the Americas. Lower-income countries and populations face significant barriers to accessing preventive care and long-term management of conditions such as hypertension and diabetes.6 Limited screening, medication access, and culturally adapted interventions hinder risk-factor control. Addressing metabolic stroke drivers requires public health and structural reforms improving access and continuity.41,43 Behavioral risk factors and social determinants of health Social determinants of health increasingly contribute independently to stroke risk, particularly among minoritized populations. In a large Hispanic/Latino cohort, cumulative exposure to low income, unemployment, discrimination, chronic stress, and limited social support was associated with higher odds of stroke and transient ischemic attack, independent of vascular risk factors.45 Behavioral risk factors substantially drive the growing stroke burden in LAC. Globally and in LAC, these risks contribute more to stroke among individuals under 50 years, whereas metabolic factors predominate after 50. Tobacco use remains prominent, particularly in men, accounting for up to 6.5% of stroke-related DALYs in Tropical Latin America in 2021. GBD 2023 data indicate that tobacco use accounts for up to 13.4% of stroke-related DALYs in regions of the Americas. High sodium intake and diets low in fruits, vegetables, and whole grains further increase cerebrovascular risk. In 2021 Andean Latin America, dietary risks, particularly low fruit intake, accounted for 4.8% of stroke-related DALYs. In Central Latin America, insufficient physical activity contributed 2.6% of stroke DALYs. These behaviors are closely linked to rising hypertension, obesity, and metabolic syndrome, increasingly prevalent across the region.44 Rising risk factors in LAC reflect rapid urbanization, increased ultra-processed food availability, sedentary work, and limited infrastructure for physical activity.6,44 This transition has particularly impacted younger populations, contributing to earlier onset of metabolic disorders and increasing the stroke burden in economically active age groups.5 Cultural and economic barriers limit healthy behaviors in LAC. Communities often lack affordable fresh products, safe spaces for physical activity, and culturally tailored education. Economic inequality promotes reliance on energy-dense diets, while public health interventions miss Indigenous and marginalized populations.43,46 The lack of effective primary care and community-level interventions exacerbates these disparities, deepening the structural determinants that perpetuate poor cardiovascular health outcomes.47 To address these challenges, public health strategies must go beyond individual behavior change and adopt systemic approaches. These include national policies to reduce sodium and trans fats in processed foods, taxes on sugary beverages, and expanded tobacco control measures. Infrastructure investments should promote active transportation and ensure safe spaces for recreation.41,43,47 Integrating culturally sensitive education and risk screening into primary care, especially underserved regions, is essential to reduce stroke burden and improve cardiovascular equity across the Americas.44 Under-recognized risk factors for stroke Environmental and occupational risk factors Air pollution and lead exposure are increasingly recognized contributors to stroke burden across the Americas, particularly in LMICs. In LAC, ambient particulate matter and household solid fuel use remain major sources. In 2021, ambient air pollution accounted for 16.6% of global stroke DALYs, and household air pollution for 11.2%, with similar patterns in the Americas. Similar proportions are observed in GBD 2023 data, with particulate matter air pollution accounting for up to 11.1% of stroke-related DALYs in regions of the Americas. For subarachnoid hemorrhage, ambient air pollution contributed 14.2% of DALYs and household air pollution 10.3%, comparable to smoking.1 In the Americas, lead exposure remains a key driver of stroke. GBD 2023 attributes about 3.7% of global stroke DALYs to lead and shows increases since 1990. Although contributions declined in regions, lead-attributable burden has risen in many LMIC settings, including parts of Latin America, underscoring exposure-reduction policies.1,48 Arsenic contamination in drinking water, even at low concentrations, has been associated with an increased risk of ischemic stroke. In Michigan, where median arsenic levels in some counties reached 1.83 μg/L and up to 7.78 μg/L in certain zip codes, adjusted analyses showed a significant association between arsenic exposure and ischemic stroke hospitalizations, with a relative risk of 1.031 (95% confidence interval (CI): 1.011–1.051) per μg/L increase in arsenic concentration.49 These findings suggest that chronic low-level arsenic exposure may contribute to stroke risk through mechanisms such as endothelial dysfunction, oxidative stress, and atherosclerosis, particularly in populations already burdened with other vascular risk factors.50 These findings underscore the need for public health policies addressing environmental toxins. Lead-induced hypertension and air pollution amplify metabolic risks, making integrated environmental interventions essential for reducing stroke burden across the Americas.51 Obstructive sleep apnea Obstructive sleep apnea (OSA) is an increasingly recognized but underappreciated stroke risk factor in the Americas. Although associated with metabolic syndrome, elevated BMI, and type 2 diabetes, particularly prevalent in LMICs, OSA is an independent contributor to stroke through intermittent hypoxia, autonomic dysregulation, endothelial dysfunction, and prothrombotic pathways. In high-income countries such as the United States and Canada, OSA prevalence is high, paralleling rising obesity rates.52 A population-based study in São Paulo found a 32.8% prevalence of OSA syndrome among adults aged 20–80 years. Male sex, older age, and obesity were strongly associated with higher OSA risk, with odds ratios increasing significantly in individuals over 60.53 While not always included in conventional stroke risk models, evidence increasingly suggests that untreated OSA can elevate the risk of ischemic stroke and intracerebral hemorrhage through mechanisms such as intermittent hypoxia, systemic inflammation, and sympathetic activation.54 Despite this, OSA remains underdiagnosed in many healthcare settings, particularly among individuals with high BMI, who are also more likely to experience other metabolic risk factors such as hypertension, diabetes and atrial fibrillation.55 In LAC, where healthcare access disparities are more pronounced, the diagnosis and treatment of sleep apnea face additional challenges.56 The intersection of high obesity rates and limited screening infrastructure exacerbates the burden of OSA-related complications, including stroke.55 Epidemiological data from the region show growing concern over behavioral and metabolic risks, yet sleep-disordered breathing is rarely addressed in stroke prevention strategies.1,5 Given OSA's cerebrovascular risk, Americas' public health frameworks must prioritize sleep apnea detection and management in populations with obesity and cardiovascular comorbidities. Poor oral health Emerging evidence links poor oral health, particularly periodontal disease, to stroke pathogenesis through systemic inflammation that promotes endothelial dysfunction and atherosclerosis, especially in inflammation-driven ischemic stroke. In LAC, oral health remains under-recognized as a public health priority, despite its high prevalence and systemic impact. A review of 35 studies from 12 Latin American and Caribbean countries found severe periodontitis prevalence ranging from 5.8% to 49.7% in adults, while moderate to severe disease affected 15.3% of adolescents. The burden is worsened by socioeconomic inequalities, limited integration of oral and primary care, and low public awareness.57 The American Heart Association has recognized periodontitis as a potential non-traditional risk factor for cardiovascular events, and similar associations have been reported in stroke epidemiology literature.58,59 In populations with limited access to preventive and restorative dental care, common in underserved communities across the Americas, this risk may be magnified, contributing to stroke disparities. Epidemiological data suggest improving oral hygiene and dental access may cost-effectively reduce inflammation and stroke risk. Integrating oral health into prevention policies addresses clinical and social determinants across the Americas.60 Chagas and other infectious diseases Chagas disease, caused by Trypanosoma cruzi, is an endemic parasitic condition in several Latin American countries, including Brazil, Bolivia, and Argentina, and represents a significant and underrecognized contributor to stroke burden in the region.61, 62, 63 Despite methodological challenges, estimates place global Chagas prevalence at 5.7–8.3 million in the early 2010s, costing US$7.2 billion annually and ∼810,000 DALYs yearly. Recent GBD data indicate 6.3 million cases in 2021, reflecting an 11% decline from 1990 to 2019 globally.63 A population-based cohort study conducted in Bambuí, a city in southeastern Brazil, assessed the association between T. cruzi infection and stroke mortality over a decade of follow-up. Between 1997 and 2007, the cohort accumulated 9740 person-years of observation, with a baseline T. cruzi infection prevalence of 37.5%. Stroke mortality was 4.62 per 1000 person-years. T. cruzi infection increased stroke-related death risk (adjusted HR 2.36, 95% CI 1.25–4.44). Elevated B-type natriuretic peptide independently predicted mortality (adjusted HR 2.72, 95% CI 1.25–5.91).43,64 Chronic cardiac manifestations of Chagas disease confer cardioembolic risk and ischemic stroke, driven by myocardial damage, apical aneurysms, and intracardiac thrombi. The disease disproportionately affects underserved rural populations, amplifying stroke risk through biological and healthcare inequities.65 Despite advances in vector control and improved diagnostic tools, Chagas disease remains a neglected tropical condition with limited integration into national stroke prevention strategies across Latin America.65 According to the Burden of Stroke and Population-Attributable Fractions of Risk Factors in LAC, Chagas disease is not explicitly listed among major risk clusters like hypertension or obesity, however its role in cardioembolic stroke is increasingly recognized in regional analyses.61,66 Integrating Chagas disease into cardiovascular public health strategies, with early detection and treatment, is essential to reduce stroke in endemic settings.65 Several other preventable infections common in the Americas contribute to stroke risk through distinct mechanisms. Dengue fever can trigger vasculitis and coagulopathy, causing ischemic and haemorrhagic stroke. Zika virus is linked to vascular inflammation, while tuberculous meningitis induces cerebral vasculitis. HIV increases stroke risk through chronic inflammation, opportunistic infections, and coagulopathy, underscoring the enduring infection and stroke relationship. These associations underscore the persistent and relevant interplay between infection and stroke in LMIC countries, where infectious diseases remain a substantial contributor to cerebrovascular burden.67,68 Conclusion Stroke remains a leading cause of death and disability across the Americas, with its burden disproportionately affecting marginalized populations.4 The persistence of racial, ethnic, and socioeconomic disparities, particularly among Indigenous, Afro-descendant, and rural communities, reflects deep-rooted inequities in access to acute care, rehabilitation, and preventive services.6 Environmental and occupational exposures, such as air pollution and lead, further exacerbate stroke risk, especially in LMICs where regulatory enforcement is limited.69 A wide range of modifiable risk factors, including hypertension, obesity, diabetes, smoking, physical inactivity, poor diet, and sleep-disordered breathing, contribute to the growing stroke burden.1,5 In addition, emerging yet underrecognized contributors such as poor oral health, Chagas disease, and other infections underscore the need for broader, interdisciplinary prevention frameworks.57,60,65 These risk factors are tightly interwoven with social determinants of health, requiring more than individual-level interventions. To reduce stroke incidence and improve outcomes, countries across the Americas must implement region-specific strategies integrating evidence-based care and structural reforms. Priorities include culturally tailored community programs, equitable expansion of stroke infrastructure, strengthened surveillance with disaggregated data, and inclusion of environmental risk factors in prevention policies. Equity-focused, locally adapted approaches, supported by sustained collaboration among health systems, academia, policymakers, and governments, are essential to reduce the region's stroke burden and advance cardiovascular health. Contributors GSS, JDD, and PL conceived the idea and designed the paper. GSS and JDD contributed equally extracting, verifying, and processing all the underlying data, and producing the tables and figures and are co-first authors. CT and TK conducted the systematic search strategy, guided by GSS and JDD. GSS and JDD drafted the manuscript with contributions from PL. All authors reviewed the manuscript and contributed important intellectual content to the study and commented critically on the manuscript. All authors have full access to all the data in the study, accept accountability for the overall work, and the corresponding author (GSS) had the final responsibility for submitting the manuscript for publication. Data sharing statement All data are available in the article and Supplementary materials. Use of artificial intelligence During the preparation of this manuscript, we used ChatGPT (OpenAI, GPT-4, May 2024 version) to assist with language correction and improving readability. The AI tool was not used to generate scientific content, analyze or interpret data, or draw conclusions. All outputs were carefully reviewed and edited by the authors to ensure accuracy and appropriateness. The prompt used was: “Please help improve the grammar and clarity of the following paragraph without changing its scientific meaning.” The use of ChatGPT was conducted under full human oversight and in accordance with ethical guidelines. Disclaimer RM, PO, and AR are staff members of the Pan American Health Organization. The authors alone are responsible for the views expressed in this publication, and do not necessarily represent the decisions or policies of the Pan American Health Organization. Declaration of interests GSS: Received grant funding from the Brazilian Ministry of Health for the Optimal and Resilient Trials. She also received consulting fees from Bayer and AstraZeneca; honoraria for lectures or presentations from Bard and AstraZeneca; travel support from Boehringer Ingelheim; and has served on an Advisory Board for Bayer. BO: Serves as Editor-in-Chief of the Journal of the American Heart Association, President of the Society for Equity Neuroscience, and Member of the Board of the World Stroke Organization. Receives grants from the US National Institutes of Health (Principal Investigator). CA: Received honoraria as speaker from Boehringer Ingelheim. TFAG: Received honoraria as speaker from Roche and Boehringer Ingelheim. PA: Received honoraria as speaker from Boehringer Ingelheim, Abbott, Ipsen, Boston Scientific and Knight Therapeutics; support for attending meetings from Boehringer Ingelheim; steering committee member for the Oceanic stroke trial (Population Health Research Institute). MAB: Received honoraria as speaker from Roche and Boehringer Ingelheim. HB: Received payment or honoraria for lectures from Novartis and Adium Colombia. VCN: Received honoraria from Boehringer Ingelheim, AstraZeneca and Sanofi; support for attending meetings from Boehringer Ingelheim. LAC: Received grants from the World Stroke Organization and Angels Initiative/Boehringer Ingelheim; consulting fees from Allm, AstraZeneca and ISchemaView; honoraria for lectures from AstraZeneca, Servier, ISchemaView and Boehringer Ingelheim; support for attending meetings from Boehringer Ingelheim. ACS: Received speaker fees from Boehringer Ingelheim. PML: Received research support from Boehringer-Ingelheim for the RECCA registry (payment to institution); steering committee member for the Librexia trial funded by Johnson & Johnson (payment to institution and author); advisory board member for Bristol Myers Squibb and Pfizer (payment to author); honoraria for lectures from Novartis, Elea-Exeltis, Ferrer, ITF, Axon Pharma and educational activities (ANGELS) supported by Boehringer-Ingelheim; support for attending meetings from the Iberoamerican Stroke Society and Global Stroke Initiative; advisory board participation for Pfizer; President of the Iberoamerican Stroke Society (SIECV). PMV: Received research grants from ANID Fondecyt Regular (grant 1221837) and Pfizer (research grant 76883481, paid to the institution); speaker fees from Boehringer Ingelheim; and support from Boehringer Ingelheim for a Research Fellow program (paid to the institution). SS: Received grant support from NIH and Genentech. VU: Received grant from Genentech, Inc. AR: Participation on advisory boards or DSMB from Boston Scientific, AstraZeneca, Shionogi, Brainomix and Chiesi. CSA: Received grants from the National Health and Medical Research Council (NHMRC) of Australia and the Medical Research Foundation (MRF) of the UK, and funding from AstraZeneca Australia (funds paid to his institution); consulting fees from Auzone Pharma and AstraZeneca; Chair of several Data Safety Monitoring Boards for trials in China (modest sitting fees); Editor-in-Chief of Cerebrovascular Diseases, Vice-President-elect of the World Stroke Organization, and Associate Editor of the International Journal of Stroke. FF: Consulting fees from Neurive and Abbott. RGT: Received honoraria for lectures from Novartis, Ipsen and Boehringer Ingelheim; support for attending meetings from Boehringer Ingelheim. JCC: Received honoraria as speaker in educational events from Boehringer Ingelheim; support for attending international conferences from Boehringer Ingelheim; participation in the Angels Initiative Steering Committee. JDBD: Received honoraria for lectures from Medtronic; support for attending meetings from LINNC and Microvention; Assistant Editor of the Journal of Neurointerventional Surgery. OMPN: Consulting fees from Boehringer-Ingelheim, AstraZeneca, Bristol Myers Squibb and Allm Inc; honoraria for lectures from Boehringer-Ingelheim and AstraZeneca. ARab: Royalties from Elsevier and Springer (authored books) and Wolters Kluwer (UpToDate section editor); participation on advisory boards/committees for Boston Scientific, Boehringer Ingelheim, Shionogi, Ceribell and Chiesi. SFA: Received grants/contracts from Bayer for a clinical trial (payments made to him and his institution); payment or honoraria for lectures or presentations from AstraZeneca and Silanes; support for attending meetings from AstraZeneca and Raffo; and participation on a Data Safety Monitoring Board for AstraZeneca. VVO: Received a research grant from Boehringer Ingelheim for a local stroke project at Clínica Alemana de Santiago; honoraria for lectures from Novo Nordisk and Pfizer; and support from Boehringer Ingelheim for attending a stroke meeting in 2025. VN: Support for travel and participation in the European Stroke Congress funded by Boehringer Ingelheim. ABCQ: Support for attending meetings from Boehringer Ingelheim. AMJ: Received honoraria as a speaker from Boehringer Ingelheim; and honoraria from Boehringer Ingelheim as part of the Angels Initiative Steering Committee. NNE: Received honoraria for lectures and presentations from Asofarma; and support for attending meetings and/or travel from Moleac. All other authors declare no conflicts of interest related to this manuscript. Acknowledgements This narrative review was undertaken without dedicated funding. Footnotes Supplementary data related to this article can be found at https://doi.org/10.1016/j.lana.2026.101466. Supplementary data Supplementary Material References Associated Data Supplementary Materials Supplementary Material